871024-38-3

Basic information

• Product Name: 4-Chloro-5-Methyl-5H-pyrrolo[3,2-d]pyriMidine
• Synonyms: 4-Chloro-5-Methyl-5H-pyrrolo[3,2-d]pyriMidine;4-Chloro-5-Methyl-5H-pyrr...
• CAS NO: 871024-38-3
• Molecular Formula: C₇H₆ClN₃
• Molecular Weight: 167.59564
• Mol File: 871024-38-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Chloro-5-Methyl-5H-pyrrolo[3,2-d]pyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-5-Methyl-5H-pyrrolo[3,2-d]pyriMidine(871024-38-3)
• EPA Substance Registry System: 4-Chloro-5-Methyl-5H-pyrrolo[3,2-d]pyriMidine(871024-38-3)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 871024-38-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-5-Methyl-5H-pyrrolo[3,2-d]pyriMidine serves as a crucial intermediate in the synthesis of a range of pharmaceuticals, particularly those with antiviral and anticancer properties. Its unique molecular structure makes it a valuable building block for the development of innovative drugs and therapeutic agents.
Used in Chemical Research:
4-Chloro-5-Methyl-5H-pyrrolo[3,2-d]pyriMidine also plays a significant role in chemical research, where it is utilized to explore new chemical reactions, mechanisms, and the synthesis of novel heterocyclic compounds.
Used as a Reference Standard in Analytical Chemistry:
Due to its well-defined chemical and physical properties, 4-Chloro-5-Methyl-5H-pyrrolo[3,2-d]pyriMidine is employed as a reference standard in various analytical techniques, ensuring the accuracy and reliability of experimental results.

Upstream product

• 84905-80-6 4-Chloro-5H-pyrrolo[3,2-d]pyrimidine 
• 74-88-4 methyl iodide 
• 66-27-3 Methyl methanesulfonate 

Downstream Products

• 919278-66-3 3-[(5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)oxy]aniline 
• 919278-08-3 4-[(5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)oxy]aniline 
• 919278-64-1 ethyl {4-[(5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)oxy]-phenyl}acetate 
• 919278-70-9 4-[(5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)oxy]benzoic acid 
• 919278-09-4 2-chloro-4-[(5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-oxy]aniline 
• 919278-29-8 2-methoxy-4-[(5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-oxy]aniline 
• 919278-69-6 3-{[(5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)oxy]methyl}aniline 
• 919278-72-1 5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-ol 
• 875339-19-8 4-(2-fluoro-4-nitrophenoxy)-5-methyl-5H-pyrrolo[3,2-d]pyrimidine 
• 940305-25-9 methyl 3-{2-chloro-4-[(5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino]phenoxy}benzoate 
• 919278-51-6 4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine-6-carbonitrile 
• 1346176-18-8 N-{3-chloro-4-[3-(trifluoromethoxy)phenoxy]phenyl}-5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine hydrochloride 
• 1346176-16-6 N-[3-chloro-4-(3-chlorophenoxy)phenyl]-5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine hydrochloride 
• 1346176-17-7 N-{3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine hydrochloride 

Relevant articles and documents

PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS

The present invention relates to compounds of formulae I, or pharmaceutically acceptable salts or esters thereof, wherein: R1 is selected from H and CO-NR8R9, wherein R8 and R9 are each independently

Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold

Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, lapatinib, is currently approved for breast cancer. To develop novel HER2/EGFR dual kinase inhibitors, we designed and synthesized pyrrolo[3,2-d]pyrimidine derivatives capable of fitting into the receptors' ATP binding site. Among the prepared compounds, 34e showed potent HER2 and EGFR (HER1) inhibitory activities as well as tumor growth inhibitory activity. The X-ray cocrystal structures of 34e with both HER2 and EGFR demonstrated that 34e interacts with the expected residues in their respective ATP pockets. Furthermore, reflecting its good oral bioavailability, 34e exhibited potent in vivo efficacy in HER2-overexpressing tumor xenograft models. On the basis of these findings, we report 34e (TAK-285) as a promising candidate for clinical development as a novel HER2/EGFR dual kinase inhibitor.

Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring

Purine analogs modified in the five-membered ring have been synthesized and examined for antibacterial activity against Mycobacterium tuberculosis H 37Rv in vitro employing the microplate alamar blue assay (MABA). The 9-deaza analogs were only

Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d] pyrimidine derivatives: Novel VEGFR2 kinase inhibitors binding to inactive kinase conformation

We synthesized a series of pyrrolo[3,2-d]pyrimidine derivatives and evaluated their application as type-II inhibitors of vascular endothelial growth factor receptor 2 (VEGFR2) kinase. Incorporation of a diphenylurea moiety at the C4-position of the pyrrolo[3,2-d]pyrimidine core via an oxygen linker resulted in compounds that were potent inhibitors of VEGFR2 kinase. Of these derivatives, compound 20d showed the strongest inhibition of VEGF-stimulated proliferation of human umbilical vein endothelial cells (HUVEC). The co-crystal structure of 20d and VEGFR2 revealed that 20d binds to the inactive form of VEGFR2. Further studies indicated that 20d inhibited VEGFR2 kinase with slow dissociation kinetics and also inhibited PDGFR and Tie-2 kinases. Oral administration of the hydrochloride salt of 20d at 3 mg/kg/day showed potent inhibition of tumor growth in a DU145 human prostate cancer cell xenograft nude mouse model.

FUSED HETEROCYCLIC COMPOUND

The present invention provides a fused heterocyclic compound having a tyrosine kinase inhibitory action, which is represented by the formula: wherein R1 is a hydrogen atom, a halogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom; R2 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom, or R1 and R2, or R2 and R3 are optionally bonded to each other to form an optionally substituted ring structure; R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to the carbon atom on ring A to form an optionally substituted ring structure; ring A is an optionally substituted benzene ring; and ring B is (i) an optionally substituted fused ring, or (ii) a pyridine ring having optionally substituted carbamoyl (the pyridine ring is optionally further substituted).

INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING

The invention relates to the inhibition of vascular endothelial growth factor (VEGF) receptor signaling and hepatocyte growth factor (HGF) receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions